Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? "Iron Carboxy Maltose or Iron Sucrose?"

IF 0.7 4区医学 Q4 MEDICAL LABORATORY TECHNOLOGY

Clinical laboratory Pub Date : 2024-10-01 DOI:10.7754/Clin.Lab.2024.240341

Turker Emre, Yalcin Gokmen

{"title":"Do Parenteral Iron Therapies Preserve or Deteriorate Kidney Functions? \"Iron Carboxy Maltose or Iron Sucrose?\"","authors":"Turker Emre, Yalcin Gokmen","doi":"10.7754/Clin.Lab.2024.240341","DOIUrl":null,"url":null,"abstract":"Background: Treatment of end stage renal disease (ESRD) is based on preserving renal functions. Since renal anemia is frequently detected, we use parenteral iron treatments in patients with chronic kidney disease (CKD). However, there need to be more precise and sufficient studies on the effect of these treatments on the rate of decrease in the glomerular filtration rate (GFR). Therefore, we conducted a study comparing the rates of change in renal function in patients who had used parenteral iron for at least five years.Methods: Our study is a retrospective cohort study, and 180 patients with CKD (86 women, 94 men, mean age: 63.5 ± 11.4 years) who had been followed and treated in nephrology outpatient clinics for at least five years and met the study criteria were included in the study. Patients were divided into three groups for iron therapy: not receiving iron therapy, iron carboxy maltose (ICM), and iron sucrose (IS) parenterally. Each group consisted of 60 people. The first and last creatinine and GFR values were compared for a 5-year follow-up in each group.Results: There was no significant difference between the two groups, those using and those not using iron, regarding creatinine increase and GFR decrease rate. Additionally, no significant difference was detected in the GFR decline rates of patients using ICM and IS.Conclusions: This study reduces the concerns that correcting anemia through parenteral iron therapy in patients with CKD may harm renal function.","PeriodicalId":10384,"journal":{"name":"Clinical laboratory","volume":"70 10","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical laboratory","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7754/Clin.Lab.2024.240341","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Treatment of end stage renal disease (ESRD) is based on preserving renal functions. Since renal anemia is frequently detected, we use parenteral iron treatments in patients with chronic kidney disease (CKD). However, there need to be more precise and sufficient studies on the effect of these treatments on the rate of decrease in the glomerular filtration rate (GFR). Therefore, we conducted a study comparing the rates of change in renal function in patients who had used parenteral iron for at least five years.

Methods: Our study is a retrospective cohort study, and 180 patients with CKD (86 women, 94 men, mean age: 63.5 ± 11.4 years) who had been followed and treated in nephrology outpatient clinics for at least five years and met the study criteria were included in the study. Patients were divided into three groups for iron therapy: not receiving iron therapy, iron carboxy maltose (ICM), and iron sucrose (IS) parenterally. Each group consisted of 60 people. The first and last creatinine and GFR values were compared for a 5-year follow-up in each group.

Results: There was no significant difference between the two groups, those using and those not using iron, regarding creatinine increase and GFR decrease rate. Additionally, no significant difference was detected in the GFR decline rates of patients using ICM and IS.

Conclusions: This study reduces the concerns that correcting anemia through parenteral iron therapy in patients with CKD may harm renal function.

查看原文本刊更多论文

肠外铁疗法会保护还是恶化肾功能？"蔗糖羧麦芽糖铁剂还是蔗糖铁剂？

背景：终末期肾病（ESRD）的治疗以保护肾功能为基础。由于经常发现肾性贫血，我们对慢性肾脏病（CKD）患者使用肠外铁剂治疗。然而，我们需要对这些治疗对肾小球滤过率（GFR）下降速度的影响进行更精确、更充分的研究。因此，我们开展了一项研究，比较使用肠外铁剂至少五年的患者的肾功能变化率：我们的研究是一项回顾性队列研究，共纳入了 180 名在肾科门诊接受随访和治疗至少 5 年且符合研究标准的 CKD 患者（86 名女性，94 名男性，平均年龄：63.5 ± 11.4 岁）。研究人员将患者分为三组，分别接受铁剂治疗：不接受铁剂治疗组、羧基麦芽糖铁剂组（ICM）和肠外蔗糖铁剂组（IS）。每组 60 人。比较了每组随访 5 年的首次和最后一次肌酐和肾小球滤过率值：结果：使用铁剂和不使用铁剂的两组在肌酐升高率和肾小球滤过率降低率方面没有明显差异。此外，使用 ICM 和 IS 的患者的 GFR 下降率也无明显差异：这项研究减少了人们对慢性肾脏病患者通过肠外铁剂治疗纠正贫血可能损害肾功能的担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical laboratory 医学-医学实验技术

CiteScore

1.50

自引率

0.00%

发文量

494

审稿时长

3 months

期刊介绍： Clinical Laboratory is an international fully peer-reviewed journal covering all aspects of laboratory medicine and transfusion medicine. In addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies. The journal publishes original articles, review articles, posters, short reports, case studies and letters to the editor dealing with 1) the scientific background, implementation and diagnostic significance of laboratory methods employed in hospitals, blood banks and physicians'' offices and with 2) scientific, administrative and clinical aspects of transfusion medicine and 3) in addition to transfusion medicine topics Clinical Laboratory represents submissions concerning tissue transplantation and hematopoietic, cellular and gene therapies.